An expert panel will discuss the latest research on CRISPR and how to use it in biotechnology and disease research.

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions—but there is always room ...

Researchers have developed a machine learning model that predicts Cas9 proteins that can be tailored with designer properties for therapeutic use.

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR–Cas, a bacterial defence system that recognizes and slashes specific sequences in viral genomes, gave scientists the power to delete or edit genes with remarkable precision. Developed in ...

REDWOOD CITY, Calif., April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into ...

CRISPR Therapeutics has a 12-month low of $30.96 and a 12-month high of $67.88. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th.

To achieve its goal, the company essentially created a hybrid genome using CRISPR technology to cut away certain gray wolf gene variants and replace them with traits associated with dire wolves ...

CRISPR Therapeutics experienced an 12% price decline over the last week, coinciding with significant market disruption driven by escalating tariff tensions, which saw the S&P 500 and Nasdaq drop ...

Drouillard said the cuts follow a volatile few years, when the CAS skidded from a $1.6-million surplus to a deficit of more than $10 million. The agency’s budget last fiscal year was about $56 ...